Stock Comparison

AMIX vs PFE

Autonomix Medical Inc vs Pfizer Inc

The Verdict

AMIX takes this one.

Winner

AMIX

Autonomix Medical Inc

5.3

out of 10

Proceed with Caution

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

Head-to-Head

$4M

Market Cap

$146.4B

N/A

P/E Ratio

19.5

N/A

Profit Margin

11.8%

-228.8%

Return on Equity

8.4%

N/A

Debt-to-Equity

0.7

Aggressive

Overall Risk

Moderate

5.3

DVR Score

4.0

The Deep Dive

AMIX5.3/10

Autonomix Medical Inc. (AMIX) remains an extremely speculative micro-cap with immense 10x growth potential if its proprietary nerve signal analysis platform achieves clinical and regulatory success. The intrinsic market opportunity in nerve-related conditions and the potential competitive advantage are strong. Recent clinical progress, evidenced by abstract acceptance for Digestive Disease Week 20...

Full AMIX Analysis

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Full PFE Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.